ACSL4 and metabolic dysfunction-associated steatohepatitis: PXL065 has non-genomic target activities via mitochondrial pyruvate carrier and acyl- CoA synthetase 4 inhibition and is being tested in a phase 2 trial in non-cirrhotic patients with NASH (NCT04321343).